Vagus Nerve Stimulation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The vagus nerve stimulation market size is expected to increase from USD 555.15 million in 2025 to USD 598.96 million in 2026 and reach USD 969.76 million by 2031, growing at a CAGR of 10.12% over 2026-2031. This report is Segmented by Product (Implantable VNS Devices and External VNS Devices), Application (Epilepsy, Depression, and Other Applications), End User (Hospitals, Neurology Clinics, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Size and Forecasts are Provided in Terms of Value (USD) for all the Above Segments.

Global Vagus Nerve Stimulation Market Trends and Insights

Increasing Prevalence of Drug-Resistant Neurological Disorders

Across major care settings, the share of epilepsy patients classified as drug resistant remains high, with professional society communications describing a 20% to one-third range when two appropriate antiseizure medications fail to deliver sustained control. Clinical guidance continues to evolve toward earlier consideration of device-enabled neuromodulation when predicted probabilities of medication response are low, a shift that aligns with expanded programming options and longer-term benefit profiles in real-world cohorts. In treatment-resistant depression, evidence summaries describe sizable nonresponse to first-line pharmacotherapy and diminishing returns with successive switches, which raises the salience of device pathways that can deliver durable symptom relief in later lines of care. The most recent U.S. coverage reconsideration process for depression is now anchored in 24-month outcomes, including a 51.6% response rate and strong durability among earlier responders, which together inform how payers balance access and evidence requirements in the next cycle.As these dynamics converge, therapy awareness in neurology and psychiatry underscores broader applicability for both implantable and non-invasive systems in the vagus nerve stimulation market.

Shift Toward Neuromodulation Over Chronic Drug Therapy

Clinicians continue to weigh systemic side effects, adherence challenges, and quality-of-life trade-offs of multi-drug regimens against device-based neuromodulation that can be programmed and titrated over time. Longitudinal data show progressive efficacy with implantable systems in focal seizure types, reinforcing their positioning in later lines when respective surgery is contraindicated or declined. In depression, multi-year observational findings show clinically meaningful response and remission rates in cohorts that had exhausted numerous prior options, which supports a pathway to sustained benefit beyond typical pharmacologic ceilings. Head-to-head parity with non-invasive brain stimulation is not the standard of care, yet benchmark response rates for transcranial magnetic stimulation often cluster in the 50-60% range in standard programs, with durability dependent on maintenance strategies in many sites. Within the U.S., the coverage-with-evidence-development framework that constrained access to depression indications since 2019 is now under formal reconsideration, which could accelerate adoption if the final decision recognizes real-world durability in addition to symptom scales. Over the long run, health-economic analyses presented by manufacturers emphasize breakeven in a two-year window due to reductions in hospitalizations and emergency utilization, a narrative that continues to resonate with stakeholders watching the vagus nerve stimulation market.

High Upfront Cost of Implantable VNS System

Total acquisition and perioperative costs remain a near-term barrier, as implantable systems require specialist procedures, specialized surgical facilities, and ongoing follow-up programming. Further emphasizing the financial burden, a study based on a United States healthcare claims database found that the mean healthcare costs were approximately USD 123,500 per person in the 2 years prior to VNS implantation. U.S. reimbursement for end-of-service procedures has moved through proposed updates that would increase payment levels in 2026, although the direction and timing of final rulings will determine how much relief hospitals and clinics experience on cash flows. Access pathways for depression are still constrained in the United States because the current national coverage determination limits payment to coverage-with-evidence-development studies with extended follow-up. Commercial plans often require multiple medication failures and psychotherapy trials before approving implantable options, which elongates time-to-therapy for patients who remain symptomatic. Several payers classify implantable vagus nerve stimulation for depression as investigational or unproven in their 2026 policy manuals, reflecting an evidence posture that has not fully converged with multi-year observational findings. New autoimmune indications may alter the cost-benefit narrative, because the 2025 U.S. approval of neuroimmune modulation for rheumatoid arthritis arrived alongside a growth capital raise intended to support commercial rollout and real-world data generation. Manufacturers also present payer-facing analyses that place breakeven for implantable systems in a roughly two-year window due to fewer hospitalizations and emergency visits, which remains a key message in the vagus nerve stimulation market.

Other drivers and restraints analyzed in the detailed report include:

• Growing Clinical Evidence and Label Expansion
• Advancement in Device Miniaturization and Closed-Loop Systems
• Surgical Risk and Patient Reluctance

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Implantable devices held 58.10% of the vagus nerve stimulation market share in 2025, while external systems are projected to lead with a 10.64% CAGR to 2031. Expanded access for non-invasive systems after adolescent clearance in the United States, combined with outpatient usability, underpins volume gains in clinics and home settings. Department of Veterans Affairs purchasing increased meaningfully in 2024 and continued to grow in 2025, reinforcing procurement-led scale in which device training and standardized protocols can be rolled out across many centers. European policy follow-through in Belgium adds another access point, which in turn supports distribution and medical education economics outside the United Kingdom. As reimbursement channels diversify and clinical teams expand their experience sets, non-invasive options are gaining ground in the vagus nerve stimulation market for patients who do not want surgery or who benefit from rapid starts in outpatient care.

Implantable platforms continue to offer structural advantages in severe or refractory presentations, where continuous and algorithm-optimized stimulation can be programmed to long-term targets. Manufacturer reporting highlights steady neuromodulation revenue growth across 2025, with regional contributions from the United States and Europe supporting ongoing portfolio investment. Next-generation closed-loop concepts and miniaturized, battery-free implants tested in randomized trials point to shorter procedures and fewer generator exchanges over time, which could reduce barriers that have historically favored nonsurgical options. With product strategies that match patient preferences, the vagus nerve stimulation industry leans into a hybrid model, pairing robust implantable performance for highly refractory cases with non-invasive convenience where flexibility and speed matter most. As these approaches mature, diversified product lines can expand participation in the vagus nerve stimulation market across hospitals, neurology clinics, and veterans’ health systems.

Complete Report Scope:

• By Product
  • Implantable VNS Devices
  • External VNS Devices
• By Application
  • Epilepsy
  • Depression
  • Other Applications
• By End User
  • Hospitals
  • Neurology Clinics
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 58.22% of vagus nerve stimulation market share in 2025, and Asia-Pacific is poised to record an 11.93% CAGR through 2031. In the United States, the national coverage reconsideration process for depression has placed multi-year outcomes at the center of policy debate, which could affect access and utilization patterns across both implantable and non-invasive systems. 2024 financial disclosures showed steady gains in U.S. neuromodulation revenue, indicating stable demand through provider channels that rely on consistent programming and follow-up. Federal purchasing has become a meaningful driver for non-invasive devices, with 2024 veterans’ system sales cited as a key growth component and 2025 revenues reaching near USD 32 million on a company-reported basis. These signals are consistent with a maturing channel strategy in the vagus nerve stimulation market that blends hospital systems, academic networks, and national payers.

Europe retained a significant portion of 2025 demand and displayed policy movement for non-invasive coverage in Belgium, which can catalyze broader discussions across neighbouring payers. The 2025 reimbursement decision for a cervical non-invasive system provides a concrete example of how headache and migraine indications can open a toehold for other evidence-based uses in neuromodulation. Ongoing portfolio updates from manufacturers and academic partners complement these policy developments, and they position Europe to integrate device evidence into neurology and rheumatology pathways over the forecast window.

Asia-Pacific’s long-run growth trajectory ties to clinic readiness, patient access programs, and the diffusion of newer device designs. Countries such as China and Japan have streamlined medical device approval pathways in recent years, accelerating the entry of innovative implantable and non-invasive VNS systems. In China, reforms by the National Medical Products Administration (NMPA) have reduced device review timelines, while Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) continue to prioritize innovative neurological therapies under fast-track programs. These regulatory improvements are encouraging multinational manufacturers to expand their footprint across the region. Reimbursement developments are also strengthening market penetration. In Japan, VNS therapy for epilepsy has been covered under the national health insurance system for several years, significantly improving patient accessibility. Similarly, Australia includes VNS therapy for drug-resistant epilepsy under the Medicare Benefits Schedule and private insurance coverage frameworks. In China, inclusion of more neurological treatments under the National Reimbursement Drug List (NRDL) and provincial reimbursement programs is gradually improving affordability for advanced device-based therapies. Recent randomized research on closed-loop miniaturized implants has showcased at-home functional gains in chronic stroke cohorts, which may inform therapy adoption in rehabilitation hubs across developed APAC markets over time. As more trials launch across neurology and autoimmune conditions, providers in major cities can leverage international findings to build multidisciplinary programs that align with local payer requirements. This foundation supports a durable gradient for adoption in the vagus nerve stimulation market over the forecast horizon.

List of Companies Covered in this Report:

• Adriakaim, Inc.
• Beijing PINS Medical Co., Ltd
• Bionics Institute
• Brain Control Co. Ltd.
• electroCore, Inc.
• Evren Technologies, Inc.
• LivaNova
• MicroTransponder Inc.
• Neuropix
• Parasym
• Pulsetto
• SetPoint Medical
• Soterix Medical
• tVNS Health GmbH
• X Nerve
• ZENOWELL

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support